Long QT Syndrome — Med2Date

📋 Key Information Summary

📋

Long QT syndrome (LQTS) is a disorder of cardiac repolarisation characterised by prolongation of the corrected QT interval (QTc) on ECG, predisposing to torsades de pointes (TdP) ventricular tachycardia and sudden cardiac death (SCD).
Congenital LQTS is caused by pathogenic variants in genes encoding cardiac ion channels; the three most common subtypes — LQTS1 (KCNQ1), LQTS2 (KCNH2), and LQTS3 (SCN5A) — account for >90% of genotype-positive cases.
Acquired LQTS is most frequently drug-induced (antiarrhythmics, antipsychotics, antibiotics, antiemetics) but may also result from electrolyte disturbances, hypothyroidism, or structural heart disease.
Diagnosis rests on the Schwartz score incorporating ECG findings, clinical history, and family history; QTc ≥470 ms in males or ≥480 ms in females on a resting 12-lead ECG is highly suggestive.
Genetic testing is indicated in patients with a Schwartz score ≥3.5, unexplained syncope, or a first-degree relative with confirmed LQTS; available through Australian clinical genetics services (MBS item 73291).
LQTS1 triggers include swimming and exertion; LQTS2 triggers include auditory stimuli and emotional stress; LQTS3 events often occur at rest or during sleep.
Non-selective beta-blockers (nadolol, propranolol) are first-line therapy for congenital LQTS; atenolol and metoprolol are less effective and not recommended as primary agents.
Left cardiac sympathetic denervation (LCSD) is an option for patients with recurrent events on beta-blockers or those intolerant of beta-blockade; performed at select Australian centres.
ICD implantation is recommended for survivors of cardiac arrest and should be considered for patients with recurrent syncope on maximised beta-blocker therapy.
All patients must avoid QT-prolonging medications; maintain an updated QT-drug list via crediblemeds.org (QTDrugs database). Pharmacy alert systems and My Health Record annotations are recommended.
Electrolyte correction — ensure serum potassium ≥4.0 mmol/L and magnesium ≥0.8 mmol/L; hypokalaemia is the single most important modifiable risk factor for TdP.
Paediatric considerations: LQTS1 and LQTS2 present in childhood; swimming restrictions for LQTS1; beta-blocker doses weight-based; family screening of first-degree relatives is mandatory.
Aboriginal and Torres Strait Islander patients face barriers to specialist cardiac and genetic services in remote areas; telehealth ECG review and culturally safe cascade screening programmes are essential.

Introduction & Australian Epidemiology

Long QT syndrome (LQTS) is an inherited or acquired channelopathy of cardiac repolarisation that predisposes affected individuals to the polymorphic ventricular tachycardia torsades de pointes (TdP) and sudden cardiac death (SCD). The condition is characterised by prolongation of the QT interval on the surface electrocardiogram (ECG), reflecting delayed repolarisation of ventricular myocytes due to dysfunction of membrane ion channels responsible for the cardiac action potential.

Congenital LQTS is caused by pathogenic variants in genes encoding potassium or sodium channel subunits, inherited in an autosomal dominant pattern (Romano-Ward syndrome) or, rarely, in a recessive pattern associated with sensorineural deafness (Jervell and Lange-Nielsen syndrome). Over 17 genes have been implicated, but three major subtypes — LQTS1 (KCNQ1), LQTS2 (KCNH2), and LQTS3 (SCN5A) — account for more than 90% of genotype-positive cases.

Acquired LQTS is considerably more prevalent and is most commonly iatrogenic, resulting from exposure to medications that block the hERG (IKr) potassium channel. Numerous drug classes are implicated, including Class IA and III antiarrhythmics, certain antibiotics (fluoroquinolones, macrolides), antipsychotics (haloperidol, droperidol, ziprasidone), antiemetics (ondansetron, domperidone), and methadone.

⚠️

Australian prevalence: The estimated prevalence of congenital LQTS in Australia is approximately 1 in 2,000 live births. LQTS is recognised as a significant contributor to sudden unexplained death in the young (SUDY), with genetic cardiac conditions accounting for up to 40% of SUDY cases in Australian coronial studies.

In Australia, the National Coronial Information System (NCIS) and the SADS (Sudden Arrhythmic Death Syndrome) Foundation have highlighted the burden of inherited arrhythmia syndromes. SADS Australia estimates that genetic cardiac conditions cause approximately 500 sudden cardiac deaths per year in Australians under 50, with LQTS being a leading identified cause. The Cardiac Society of Australia and New Zealand (CSANZ) provides expert consensus guidance on the evaluation and management of inherited arrhythmia syndromes.

Key Australian resources include the SADS Foundation Australia, the CSANZ Inherited Arrhythmias Working Group, and the Royal Australasian College of Physicians (RACP) guidelines on genetic evaluation of sudden cardiac death. Genetic testing is available through public clinical genetics services in each state and territory, with MBS rebates under items for genomic sequencing where criteria are met.

Congenital LQTS: Genetics & Types

Congenital LQTS is caused by loss-of-function or gain-of-function variants in genes encoding cardiac ion channel α-subunits or their regulatory proteins. The three major subtypes have distinct genetic aetiologies, clinical triggers, ECG features, and responses to therapy.

Subtype	Gene	Channel / Current	Prevalence	Typical Triggers	ECG Features
LQTS1	KCNQ1	↓ IKs (slow delayed rectifier K⁺)	~40% of genotype+ cases	Exercise (especially swimming), emotional stress, sudden auditory stimuli (alarm clock)	Broad-based T wave; QTc often normalises at rest but prolongs with sympathetic activation
LQTS2	KCNH2 (hERG)	↓ IKr (rapid delayed rectifier K⁺)	~30% of genotype+ cases	Emotional stress, startle, post-partum period, auditory stimuli	Low-amplitude bifid or notched T wave in precordial leads
LQTS3	SCN5A	↑ INa (persistent inward Na⁺ current)	~10% of genotype+ cases	Rest, sleep, bradycardia, fever	Late-onset peaked/biphasic T wave; long isoelectric ST segment

Less Common Subtypes

Rare subtypes (LQTS4–LQTS17) account for <5% of genotype-positive cases and include variants in ANK2 (LQTS4), KCNE1 (LQTS5), KCNE2 (LQTS6), KCNJ2 (LQTS7, Andersen-Tawil syndrome), CACNA1C (LQTS8, Timothy syndrome), CAV3 (LQTS9), KCNJ5 (LQTS13), and SCN4B (LQTS10). Many of these overlap with catecholaminergic polymorphic ventricular tachycardia (CPVT) or Brugada syndrome phenotypes.

Jervell and Lange-Nielsen Syndrome

Autosomal recessive inheritance of biallelic KCNQ1 or KCNE1 pathogenic variants causes the Jervell and Lange-Nielsen syndrome (JLNS), characterised by congenital sensorineural deafness and a severe LQTS phenotype with very long QTc intervals and a high risk of cardiac events in early childhood. JLNS prevalence is estimated at 1 in 200,000.

Genetic Testing in Australia

Genetic testing for LQTS is available through Australian clinical genetics services and should be offered to:

Patients with a Schwartz score ≥3.5 (intermediate or high probability).
Patients with unexplained syncope, seizure, or cardiac arrest where LQTS is a differential.
First-degree relatives of genotype-positive probands (cascade testing).
Cases of sudden unexplained death in the young referred for molecular autopsy.

Testing is performed by next-generation sequencing (NGS) panels targeting the major LQTS genes, with whole-exome or whole-genome sequencing available for complex phenotypes. MBS item 73291 provides a rebate for genomic testing where clinical criteria are met. Results should be interpreted by a clinical geneticist or cardiologist with expertise in inherited arrhythmias, and variant classification follows American College of Medical Genetics and Genomics (ACMG) criteria.

✅

Cascade screening: All first-degree relatives of a genotype-positive individual should undergo targeted genetic testing and clinical evaluation (ECG, exercise stress test). If the proband is genotype-negative, phenotypic screening (12-lead ECG, Holter monitoring) of first-degree relatives is recommended regardless.

Acquired LQTS: Causes & Drug-Induced

Acquired QT prolongation is far more common than congenital LQTS and is predominantly iatrogenic. Drug-induced QT prolongation results from blockade of the hERG (IKr) potassium channel encoded by KCNH2, though other mechanisms (INa augmentation, ICaL effects) are increasingly recognised. Importantly, a proportion of patients who develop drug-induced TdP harbour clinically silent pathogenic variants in LQTS genes — so-called "latent" or "concealed" congenital LQTS — which unmask under pharmacological or metabolic stress.

High-Risk QT-Prolonging Medications

Drug Class	Examples (Australian brands)	TdP Risk	PBS Status
Class III antiarrhythmics	Amiodarone (Arycor®), sotalol (Sotacor®), dofetilide	High	PBS General Benefit
Class IA antiarrhythmics	Disopyramide (Rythmodan®), procainamide	High	PBS General Benefit
Antipsychotics	Haloperidol (Haldol®), droperidol (Droleptan®), ziprasidone (Zeldox®), thioridazine	High	PBS General Benefit
Antiemetics	Ondansetron (Zofran®), domperidone (Motilium®)	Moderate	PBS General Benefit
Fluoroquinolone antibiotics	Moxifloxacin (Avelox®), ciprofloxacin (Ciproxin®)	Moderate	PBS Restricted Benefit
Macrolide antibiotics	Erythromycin, clarithromycin (Klacid®), azithromycin (Zithromax®)	Moderate	PBS General Benefit
Antifungals	Fluconazole (Diflucan®), itraconazole (Sporanox®)	Moderate	PBS General Benefit
Opioids	Methadone (Physeptone®), levomethadyl	High	PBS Authority Required
Antimalarials	Chloroquine, hydroxychloroquine (Plaquenil®)	Moderate	PBS General Benefit

Non-Drug Causes of Acquired QT Prolongation

Electrolyte disturbances: Hypokalaemia (K⁺ <3.5 mmol/L), hypomagnesaemia (Mg²⁺ <0.7 mmol/L), hypocalcaemia (Ca²⁺ <2.1 mmol/L).
Endocrine: Hypothyroidism (bradycardia-related QT prolongation), hypoparathyroidism.
Nutritional: Anorexia nervosa, liquid protein diets, celiac disease (electrolyte depletion).
Cardiac: Myocarditis, ischaemic cardiomyopathy, significant bradycardia (sinus node dysfunction, complete heart block).
Neurological: Subarachnoid haemorrhage, stroke (central sympathetic surge).
HIV infection: Direct viral myocardial effects and antiretroviral drugs (efavirenz, lopinavir/ritonavir).

🚨

Drug interaction alert: The combination of two or more QT-prolonging drugs dramatically increases TdP risk through additive or synergistic IKr blockade. Avoid prescribing two QT-prolonging agents concurrently. When unavoidable, continuous telemetry monitoring and correction of electrolytes to high-normal ranges are mandatory.

Risk Factors for Drug-Induced TdP

The following patient factors increase susceptibility to drug-induced QT prolongation and TdP:

Female sex (2–3× higher risk than males; lower repolarisation reserve).
Baseline QTc >450 ms (males) or >470 ms (females).
Age >65 years.
Heart failure (LVEF <35%) or left ventricular hypertrophy.
Bradycardia (resting HR <60 bpm).
Electrolyte abnormalities (hypokalaemia, hypomagnesaemia, hypocalcaemia).
Hepatic impairment (reduced drug metabolism).
Polypharmacy (≥5 medications).
Family history of LQTS or SCD (may harbour latent congenital LQTS).

Risk Stratification & ECG Monitoring

The Schwartz Score for Congenital LQTS

The modified Schwartz score remains the principal clinical tool for estimating the probability of congenital LQTS in the absence of genetic testing results.

Criterion	Points
ECG findings
QTc ≥480 ms	3
QTc 460–479 ms (males 450–459 ms)	2
QTc 440–459 ms	1
Torsades de pointes (TdP)	2
T-wave alternans	1
Notched T wave in 3 leads	1
Low heart rate for age	0.5
Clinical history
Syncope with stress (LQTS1/2)	2
Syncope without stress (LQTS3)	1
Congenital deafness	0.5
Family history
Family member with confirmed LQTS	1
Unexplained SCD in immediate family member <30 years	0.5

Interpretation: ≤1 point = low probability; 1.5–3 points = intermediate probability; ≥3.5 points = high probability. A score ≥3.5 warrants referral to a cardiologist with inherited arrhythmia expertise and genetic testing.

ECG Parameters & Monitoring

Accurate QTc measurement is the cornerstone of LQTS diagnosis and monitoring:

QTc formula: Bazett's correction (QTc = QT / √RR) is the standard but overcorrects at heart rates >100 bpm and undercorrects at <60 bpm. Fridericia's formula (QTc = QT / ∛RR) is more accurate at extremes of heart rate and should be used in drug safety studies.
Measurement technique: Use lead II or V5; measure from the onset of the QRS to the end of the T wave (return to T-P baseline). In bifid T waves, include the second component if the amplitude is ≥50% of the first.
Normal values: QTc <450 ms (males), <460 ms (females); borderline 450–470 ms (males), 460–480 ms (females); prolonged >470 ms (males), >480 ms (females).
Exercise stress test: Particularly useful for LQTS1. QTc prolongation during the recovery phase (minutes 1–4 post-exercise) is a hallmark. The maximum QTc during recovery >460 ms has high sensitivity for LQTS1.
Holter monitoring: 24–48 hour Holter assesses diurnal QTc variation and captures T-wave morphology changes. LQTS3 patients may show nocturnal QTc prolongation.
Epinephrine (adrenaline) provocation test: IV epinephrine infusion may unmask LQTS1 (paradoxical QTc prolongation) but requires specialist cardiac monitoring facilities and is not universally endorsed in Australia.

Risk Stratification for Cardiac Events

Low Risk

Asymptomatic LQTS

QTc 440–470 ms, no syncope, no TdP, no family history of SCD. Genotype-positive with normal QTc ("concealed" LQTS).

Setting: Outpatient cardiology follow-up; lifestyle counselling; drug avoidance

Moderate Risk

Symptomatic LQTS

QTc 470–500 ms, history of syncope (especially exercise-triggered in LQTS1), male LQTS3 with QTc >500 ms, age <10 years at first event.

Setting: Beta-blocker therapy; cardiology and genetics referral; consider ICD if recurrent events

High Risk

Cardiac Arrest / Recurrent Events

Survived cardiac arrest, recurrent TdP on therapy, QTc >500 ms, Jervell and Lange-Nielsen syndrome, syncope on beta-blocker therapy.

Setting: ICD implantation mandatory; aggressive beta-blocker therapy; LCSD consideration; tertiary centre management

⚠️

MBS items for ECG monitoring: Resting 12-lead ECG (MBS item 11707), 24-hour Holter (MBS item 11710), and exercise stress testing (MBS item 11714) are rebatable under Medicare. Genetic testing under MBS item 73291 requires clinical genetics referral.

Management: Beta-Blockers, ICD, & Drug Avoidance

Management of LQTS requires a multimodal approach combining pharmacotherapy, device therapy, lifestyle modification, and rigorous avoidance of QT-prolonging agents. Therapy should be individualised based on LQTS genotype, symptom burden, QTc duration, and patient-specific risk factors.

Beta-Blocker Therapy

Beta-blockers are first-line therapy for all congenital LQTS subtypes. They reduce adrenergic-triggered arrhythmias by attenuating sympathetic stimulation of ventricular myocytes and reducing heart rate variability. Non-selective beta-blockers with sustained plasma levels are preferred.

💊

Nadolol

Corgard® (imported) · Non-selective β-blocker · Preferred agent

Adult dose 40 mg PO daily; titrate to 80–160 mg PO daily (max 240 mg/day)

Paediatric dose 1 mg/kg/day PO; titrate to 2 mg/kg/day (max 2.5 mg/kg/day)

Route Oral

Frequency Once daily (long half-life, 20–24 hours)

Key advantage Long half-life, no first-pass metabolism, most evidence in LQTS

Renal adjustment Dose reduction required if CrCl <50 mL/min; extend dosing interval

PBS status PBS Restricted Benefit

💊

Propranolol

Inderal® · Non-selective β-blocker · Alternative agent

Adult dose 40 mg PO TDS; titrate to 120–240 mg/day in divided doses

Paediatric dose 2–4 mg/kg/day PO in 3 divided doses (max 5 mg/kg/day)

Route Oral

Frequency TDS (shorter half-life; adherence-critical)

Renal adjustment No specific adjustment; use with caution

PBS status PBS General Benefit

🚨

Critical: Atenolol and metoprolol are NOT recommended as primary therapy for LQTS. Their cardioselectivity and shorter duration of action provide inferior protection against adrenergic-triggered arrhythmias. If nadolol is unavailable (supply issues in Australia), propranolol is the preferred alternative. Never abruptly discontinue beta-blockers — rebound sympathetic activation may precipitate TdP.

LQTS3-Specific Considerations

LQTS3 (SCN5A gain-of-function) responds less well to beta-blockers, as events are often bradycardia-dependent and occur at rest or during sleep. Sodium channel blockade with mexiletine (not PBS-listed; requires Section 19 importation) or ranolazine (used off-label) may be considered as adjunctive therapy in LQTS3 patients with recurrent events. Flecainide has also been used in LQTS3 with the Brugada overlap phenotype but requires specialist supervision.

Implantable Cardioverter-Defibrillator (ICD)

ICD implantation is a life-saving intervention for high-risk LQTS patients:

Class I indication: Survivors of cardiac arrest (secondary prevention).
Class IIa indication: Recurrent syncope on maximised beta-blocker therapy; QTc >500 ms with additional risk factors.
Class IIb indication: High-risk genotype (e.g., LQTS2 with early onset, LQTS3 with QTc >500 ms) despite compliance with beta-blockers; consideration in patients unable to take beta-blockers.

ICD programming should incorporate long detection intervals to avoid inappropriate shocks for self-terminating TdP. Anti-tachycardia pacing (ATP) as first therapy is preferred. ICD implantation is performed at major Australian cardiac centres; costs are covered under Medicare for approved indications.

Left Cardiac Sympathetic Denervation (LCSD)

LCSD (video-assisted thoracoscopic sympathectomy of the lower half to one-third of the left stellate ganglion and T2–T4 ganglia) reduces sympathetic innervation to the heart. Indications include:

Recurrent syncope or TdP on maximised beta-blocker therapy.
Beta-blocker intolerance or contraindication.
Patients refusing or not meeting criteria for ICD.
ICD patients with recurrent appropriate shocks (adjunct to beta-blockers).

LCSD is available at select Australian tertiary centres (Royal Melbourne Hospital, Westmead Hospital). It reduces cardiac event rates by approximately 70–90% but is not curative — patients remain on beta-blockers and require ongoing follow-up.

Acute Management of Torsades de Pointes

🚨

Haemodynamically unstable TdP: Immediate synchronised DC cardioversion (120–200 J biphasic). If pulseless, treat as ventricular fibrillation — defibrillation, CPR, adrenaline per ALS algorithm.

Pharmacological management of recurrent/persistent TdP:

💊

Magnesium sulfate

First-line agent · Regardless of serum Mg²⁺ level

Adult dose 2 g (8 mmol) IV over 2–5 min; may repeat once after 5–15 min; infusion 1–2 g/hr IV

Paediatric dose 25–50 mg/kg IV (max 2 g); infusion 0.5–1 g/hr

PBS status PBS General Benefit

💊

Isoprenaline (isoproterenol)

Used to increase heart rate in pause-dependent TdP · Avoid in LQTS3

Adult dose 1–4 mcg/min IV infusion; titrate to HR 90–110 bpm

Contraindication LQTS3, ischaemic heart disease

PBS status PBS General Benefit (hospital)

💊

Overdrive pacing

Temporary transvenous or transcutaneous pacing

Rate 90–110 bpm to shorten QT interval and suppress ectopy

Indication Recurrent pause-dependent TdP; bridge to ICD or definitive therapy

Drug Avoidance & QT-Drug Lists

All patients with congenital or acquired LQTS must maintain strict avoidance of QT-prolonging medications. Key strategies:

Register the patient's LQTS diagnosis on My Health Record with a prominent allergy/alert flag.
Refer to the CredibleMeds QTDrugs database (crediblemeds.org) — the international gold-standard list categorising drugs as Known Risk, Possible Risk, or Conditional Risk for TdP.
Educate patients to carry a medical alert bracelet and wallet card listing QT-prolonging drug avoidance.
Ensure all prescribing clinicians, pharmacists, and emergency departments are aware of the diagnosis.
Common drugs to AVOID: ondansetron, domperidone, droperidol, haloperidol IV, methadone, fluoroquinolones (moxifloxacin, ciprofloxacin), erythromycin IV, azithromycin in high doses, amitriptyline, fluconazole in high doses, chloroquine.
Safe antiemetics: metoclopramide, prochlorperazine (Stemetil®). Safe antibiotics: amoxicillin, cephalexin (Keflex®), trimethoprim-sulfamethoxazole (use with K⁺ monitoring).

Lifestyle Modifications

LQTS1: Avoid competitive swimming and diving (high event risk); recreational swimming only with a buddy present. Avoid sudden startling noises (alarm clocks).
LQTS2: Minimise exposure to startle stimuli; emotional stress management; caution during the post-partum period (elevated risk of cardiac events).
All subtypes: Maintain adequate hydration and electrolyte intake; avoid excessive alcohol; treat fever aggressively (fever lowers IKr function and prolongs QT); avoid extreme temperatures (very hot baths/saunas).
Exercise: Most patients on beta-blockers can participate in recreational and competitive sport with appropriate counselling and genotype-specific advice. The 2015 ESC recommendations and subsequent CSANZ guidance allow competitive sport for genotype-positive/phenotype-negative patients and carefully selected phenotype-positive patients on therapy.
Pregnancy: Continue beta-blockers throughout pregnancy; nadolol and propranolol are preferred. Labetalol may be used. Monitor fetal growth (beta-blockers may cause small-for-gestational-age infants). Post-partum period is high-risk for LQTS2.

Special Populations

🤰

Pregnancy & Lactation

Beta-blockers

Continue nadolol or propranolol throughout pregnancy. Labetalol is an acceptable alternative. Atenolol is avoided in first trimester (associated with fetal growth restriction). Monitor fetal growth with serial ultrasound from 28 weeks.

Post-partum period

Highest risk period for LQTS2 — do NOT discontinue beta-blockers. Continue monitoring for 9 months post-partum. Breastfeeding is safe on nadolol and propranolol (minimal transfer).

👶

Paediatric Considerations

Presentation

LQTS1 and LQTS2 may present in infancy with bradycardia, 2:1 AV block, or T-wave alternans. JLNS presents with deafness and severe QT prolongation in early childhood. First cardiac event often occurs before age 12 in symptomatic children.

Beta-blocker dosing

Nadolol 1 mg/kg/day, titrate to 2 mg/kg/day (max 2.5 mg/kg/day). Propranolol 2–4 mg/kg/day in 3 divided doses. Weight-based dosing essential; monitor for bradycardia and hypoglycaemia.

Swimming restrictions

LQTS1: Avoid competitive swimming; recreational swimming only with trained buddy present. Lifejacket recommended. SADS Australia provides swimming safety guidance.

👴

Elderly Patients

Increased risk

Age >65 is an independent risk factor for drug-induced TdP due to reduced repolarisation reserve, renal impairment, polypharmacy, and structural heart disease. Lower starting doses of beta-blockers with careful titration.

Medication review

Conduct comprehensive medication review (consider Pharmacy Dose Administration Aids, HMR/RMMR under MBS items 900, 903). Screen all medications against CredibleMeds QTDrugs list.

🫘

Renal Impairment

Nadolol

Significantly renally cleared. Dose reduction required: CrCl 31–50 mL/min — reduce dose by 50%; CrCl 10–30 mL/min — reduce by 75% or extend interval; CrCl <10 mL/min — avoid or use very cautiously. Propranolol (hepatically cleared) is preferred in severe CKD.

Electrolyte monitoring

CKD patients are at high risk of hyperkalaemia (risk for beta-blocker-related bradycardia) or hypokalaemia (from diuretics). Target K⁺ 4.0–5.0 mmol/L. Mg²⁺ supplementation often needed.

🫁

Hepatic Impairment

Propranolol

Extensively hepatically metabolised; bioavailability increases significantly in cirrhosis. Start at 25% of standard dose; titrate cautiously. Monitor for excessive bradycardia.

Nadolol

Not hepatically metabolised — preferred in hepatic impairment (adjust for concurrent renal function).

🛡️

Immunocompromised Patients

Antibiotic selection

Avoid fluoroquinolones and macrolides (QT prolongation). Use amoxicillin, cephalexin, or trimethoprim-sulfamethoxazole where appropriate. Monitor K⁺ and Mg²⁺ closely during acute illness.

HIV patients

Screen QTc before and after starting antiretroviral therapy. Avoid lopinavir/ritonavir + QT-prolonging agents. Efavirenz may prolong QTc — monitor.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Aboriginal and Torres Strait Islander peoples experience higher rates of cardiovascular disease and sudden cardiac death compared with non-Indigenous Australians. Inherited arrhythmia syndromes, including LQTS, may contribute to the elevated burden of sudden cardiac death in young Indigenous Australians, though epidemiological data specific to LQTS in this population remain limited. The AIHW reports that cardiovascular disease is the leading cause of the life expectancy gap, and genetic cardiac conditions likely remain underdiagnosed.

Specialist access

Cardiology and clinical genetics services are concentrated in metropolitan centres. Aboriginal and Torres Strait Islander peoples in remote and very remote communities face significant barriers to specialist referral, ECG interpretation, and genetic testing. Telehealth-enabled ECG review through the Royal Flying Doctor Service (RFDS) and state-based cardiac networks can facilitate earlier diagnosis.

Genetic testing barriers

Genetic testing uptake is lower among Aboriginal and Torres Strait Islander peoples due to limited clinical genetics workforce, cultural considerations around DNA testing, and geographic remoteness. Culturally safe genetic counselling, engagement of Aboriginal Health Workers and Practitioners (AHWPs), and community-controlled health organisation (ACCHO) partnerships are essential for cascade screening programmes.

Medication access

Nadolol availability is limited in remote areas; propranolol (PBS General Benefit) is more accessible. Remote area pharmacists should ensure adequate stock of non-selective beta-blockers. Closing the Gap PBS co-payment reduces out-of-pocket medication costs for eligible Aboriginal and Torres Strait Islander patients.

Cultural safety

Engage Aboriginal Liaison Officers (ALOs) in cardiac and genetics consultations. Respect kinship obligations in family cascade screening. Use Aboriginal interpreter services where required. Discuss the spiritual and cultural meaning of genetic testing with the patient and family. Avoid assumptions about lifestyle factors — focus on empowering health literacy.

Sudden death prevention

Implement community-based cardiac screening programmes in partnership with ACCHOs. Train AHWPs in basic ECG acquisition and recognition of prolonged QTc. Provide CPR and AED training in remote communities. Ensure access to emergency medical retrieval for TdP/cardiac arrest. Register all LQTS patients on My Health Record for cross-jurisdictional alerting.

Data and research

Advocate for inclusion of Aboriginal and Torres Strait Islander peoples in national inherited arrhythmia registries. Support Indigenous-led research into the genetic epidemiology of LQTS in First Nations Australians. Collaborate with SADS Australia and CSANZ to develop culturally appropriate educational materials in community languages.

📚 References

1. Schwartz PJ, Crotti L, Insolia R. Long QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol. 2012;5(4):868–877.
2. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013;10(12):1932–1963.
3. Ackerman MJ, Priori SG, Dubin AM, et al. Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: are all beta-blockers equivalent? Heart Rhythm. 2017;14(1):e41–e44.
4. Giudicessi JR, Ackerman MJ. Genotype- and phenotype-guided management of congenital long QT syndrome. Curr Probl Cardiol. 2013;38(10):417–455.
5. Cardiac Society of Australia and New Zealand. Guidelines for the management of inherited arrhythmia syndromes. Heart Lung Circ. 2017;26(1):1–32.
6. Woosley RL, Black K, Heise CW, Romero K. CredibleMeds.org: what does it offer? Trends Cardiovasc Med. 2018;28(2):94–99.
7. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Aboriginal and Torres Strait Islander people. AIHW Cat. No. CVD 79. Canberra: AIHW; 2023.
8. Skinner JR, Crawford J, Smith W, et al. Prospective, population-based long QT molecular autopsy study of post-mortem negative sudden death in 1 to 40 year olds. Heart Rhythm. 2011;8(3):412–419.
9. SADS Foundation Australia. Sudden Arrhythmic Death Syndrome: clinical resources and family support. Available at: sads.org.au. Accessed 2024.
10. Peltenburg B, Krijnen WP, den Ruijter HM, et al. Sex differences in drug-induced QTc prolongation: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9:888403.
11. Al-Khatib SM, LaPointe NMA, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA. 2003;289(16):2120–2127.
12. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–1022.
13. Members Service Providers (MBS). Medicare Benefits Schedule — Item 73291 (Genomic sequencing). Australian Government Department of Health and Aged Care. Available at: mbsonline.gov.au. Accessed 2024.
14. Royal Australasian College of Physicians (RACP). Genetic evaluation of sudden cardiac death: position statement. Sydney: RACP; 2022.
15. Pelliccia A, Sharma S, Gati S, et al. 2020 ESC guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17–96.